Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition) ›› 2024, Vol. 11 ›› Issue (03): 121-125. doi: 10.3877/cma.j.issn.2095-8765.2024.03.002

• Original Articles • Previous Articles    

Clinical efficacy study of anti-reflux mucosal ablation in gastroesophageal reflux disease

Jing Zhang1, Jun Bai1, Yumen Chen1, Peng Zhang1, Fangfang Hou1, Junfang Wang1, Jing Sun1, Shibo Zhao1, Zhe Yang1, Yue Zhang1, Ruifang Zhang1, Hongbin Zhu1,()   

  1. 1.Department of Gastroenterology,the 983rd Hospital,Joint Logistic Support Force,Tianjin300142,China
  • Received:2023-11-27 Online:2024-08-15 Published:2024-11-22
  • Contact: Hongbin Zhu

Abstract:

Objective

Clinical studies of Anti-reflux mucosal ablation (ARMA) for gastroesophageal reflux disease (GERD) are rare. This study observed the clinical efficacy of ARMA on GERD through a retrospective study.

Methods

Retrospective analysis of the efficacy of ARMA in patients identified as GERD by 24 h dynamic esophageal pH monitoring. Efficacy was observed by 24 h dynamic esophageal pH monitoring, GERD-Q scale score and quality-of-life rating scale (SF-36) before and after 6 months. The efficacy of ARMA in different gastroesophageal reflux valve (GEFV) grades was also observed.

Results

Thirty-six patients were included in this study. Six months after ARMA, 30 patients with positive GERD-Q scores turned negative or decreased scores, with a response rate of 83.3% (30/36). 25 patients with positive GERD-Q score were cured without taking PPI, with a cure rate of 69.4% (25/36). In patients with grades Ⅰ-Ⅲ of GEFV, 24 h dynamic esophageal pH monitoring showed 6 months after surgery,with a statistically significant improvement in GERD-Q score and SF-36 score (P<0.05). At the same time,the dosage and frequency of acid reflux, heartburn, chest pain and PPI drugs were significantly improved.Meanwhile, GEFV patients with 24 h after surgery had acid mixed reflux, and their GERD-Q scores and SF-36 scores were not statistically different compared with preoperative ones (P >0.05).

Conclusion

ARMA has good efficacy in GERD patients with GEFV grade Ⅰ-Ⅲ and poor efficacy in patients with GEFV gradeⅣ.

Key words: Gastroesophageal reflux disease, Anti-reflux mucosal ablation, Gastroesophageal reflux valve

京ICP 备07035254号-20
Copyright © Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), All Rights Reserved.
Tel: 0991-8563812 E-mail: zhwsgflbzz@163.com
Powered by Beijing Magtech Co. Ltd